标题
Tolvaptan for the treatment of liver cirrhosis oedema
作者
关键词
-
出版物
Expert Review of Gastroenterology & Hepatology
Volume 8, Issue 5, Pages 461-470
出版商
Informa UK Limited
发表日期
2014-03-29
DOI
10.1586/17474124.2014.903797
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Health-related quality of life and survival in Chinese patients with chronic liver disease
- (2013) Feng Gao et al. Health and Quality of Life Outcomes
- Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial
- (2013) Kiwamu Okita et al. HEPATOLOGY RESEARCH
- Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial
- (2013) Isao Sakaida et al. HEPATOLOGY RESEARCH
- The Pharmacokinetics and Pharmacodynamics of Tolvaptan in Patients with Liver Cirrhosis with Insufficient Response to Conventional Diuretics: a Multicentre, Double-blind, Parallel-group, Phase III Study
- (2013) I Sakaida et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema
- (2013) Isao Sakaida et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects
- (2011) Susan E. Shoaf et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics, Pharmacodynamics and Safety of Tolvaptan, A Novel, Oral, Selective Nonpeptide AVP V2-receptor Antagonist: Results of Single- and Multiple-Dose Studies in Healthy Japanese Male Volunteers
- (2011) Seong Ryul Kim et al. CARDIOVASCULAR DRUGS AND THERAPY
- Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study)
- (2011) Masunori Matsuzaki et al. CARDIOVASCULAR DRUGS AND THERAPY
- Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects
- (2011) Susan E. Shoaf et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis
- (2011) Andrés Cárdenas et al. JOURNAL OF HEPATOLOGY
- A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose–response of tolvaptan in patients with decompensated liver cirrhosis
- (2010) Kiwamu Okita et al. JOURNAL OF GASTROENTEROLOGY
- Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis
- (2010) Florence Wong et al. JOURNAL OF HEPATOLOGY
- EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis
- (2010) JOURNAL OF HEPATOLOGY
- Effects of satavaptan, a selective vasopressin V2receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial
- (2008) Pere Ginès et al. HEPATOLOGY
- Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management
- (2008) Pere Ginès et al. HEPATOLOGY
- Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List
- (2008) W. Ray Kim et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now